13th International Symposium on Probiotics and Health, organized by Chinese Institute of Food Science & Technology (CIFST) and themed as “Probiotics: Technology and Industrialization”, will be held in Guangzhou, China during May 23-24, 2018. The conference is focusing on research highlights, regulation & standards, industry innovation, etc. It is one of the most important probiotics event in China.
Plenary Session 1
Session Timing: 9:40-12:05, May 23, 2018
DuPont speaker: Arthur C. Ouwehand, Ph.D., technical fellow & research manager, Global Health & Nutrition Science, DuPont Nutrition & Health.
Speech timing: 11:25-12:05, May 23, 2018
Speech topic: Support Health with Quality Probiotics
Probiotics provide, by definition, health benefits. In order to substantiate those benefits, research of appropriate quality is required. This work can start with in vitro and animal work. But, will ultimately require human intervention studies. While exploratory work can be performed in small pilot trials human studies or through post-hoc analysis of larger studies with different endpoints. In order to prove a health benefit for humans, appropriate studies need to be conducted. This means sufficient number of subjects, a priori defined primary and secondary end points as well as statistical analyses. Studies will also need to be registered in a WHO-approved registry, before starting, and there needs to be a commitment to publish the results; regardless the outcome.
For both the intervention study as well as the subsequent consumer product, probiotic quality; including safety, needs to be assured. Safety needs to be assured prior as one of the first step in the development of a new probiotic strain. For the intervention study, guaranteeing the quality is less challenging as the investigators have substantial control over the production, storage and logistics of the study products. In a commercial product, strain stability is more challenging as long (24 months) shelf-life is requested for dietary supplemented and fermented products may have challenges in maintaining a cold-chain. As a guidance for consumers correct identification, on the label, of the used strains and counts at the end of shelf-life are important quality indicators.
To what extent results from human intervention trials can be used to make health claims depends on the regulation. Here, guidance from the regulator is beneficial to both consumer and manufacturer.
Technical Session 1: Beneficial Function and Gut Health Regulation Mechanisms of Probiotics
Session timing: 9:00-12:00, May 24, 2018
DuPont host (joint): Susan Jin, Ph.D., Product Management Director Asia Pacific, Probiotics, Cultures and Food Protection Ingredients, DuPont Nutrition & Health
DuPont speaker: Amy B. Smith, Ph.D., Senior Manager, Regulatory Affairs NAFTA, & Probiotic Global Lead for Regulatory Affairs, DuPont Nutrition & Health
Speech timing: 9:00-9:40, May 24, 2018
Speech topic: Global Probiotic Best Practices for Safety and Efficacy
The global probiotics industry lacks harmonization in the areas of establishing safety, and in providing suitable efficacy. Regulatory authorities do not uniformly address probiotics as an ingredient type, leaving an unclear path for global probiotics companies to administer routinely. DuPont Nutrition & Health manufactures probiotics for use as an ingredient in foods and dietary supplements for global application. A clearly defined manufacturing process, using approved raw materials and identification standards in combination with a broad safety program allow an ideal global probiotic portfolio. Furthermore, the adaptation of a model system for proving efficacy for therapeutic benefits of probiotic strains has been adopted. A case study of compilation of efficacy for successful health claims will be presented.